SANDOZ FENOFIBRATE E TABLET
Land: Canada
Taal: Engels
Bron: Health Canada
Productkenmerken
(SPC)
17-11-2017
Sommige documenten voor dit product zijn momenteel niet beschikbaar, u kunt een verzoek sturen naar onze klantenservice en we zullen u hiervan op de hoogte stellen zodra we ze kunnen verkrijgen.
Verzend verzoek.
Verzend verzoek.
Werkstoffen:
FENOFIBRATE
Beschikbaar vanaf:
SANDOZ CANADA INCORPORATED
ATC-code:
C10AB05
INN (Algemene Internationale Benaming):
FENOFIBRATE
Dosering:
145.0MG
farmaceutische vorm:
TABLET
Samenstelling:
FENOFIBRATE 145.0MG
Toedieningsweg:
ORAL
Eenheden in pakket:
30
Prescription-type:
Prescription
Therapeutisch gebied:
FRIBIC ACID DERIVATIVES
Product samenvatting:
Active ingredient group (AIG) number: 0118895006; AHFS:
Autorisatie-status:
APPROVED
Autorisatie datum:
2012-08-02
Productkenmerken
_Sandoz Fenofibrate E Page 1 of 43_
PRODUCT MONOGRAPH
PR
SANDOZ FENOFIBRATE E
Fenofibrate tablets
48 mg and 145 mg
Manufacturer’s standard
Lipid Metabolism Regulator
Sandoz Canada Inc. Date of Revision: November 17, 2017
145 Jules-Léger
Boucherville, QC, Canada
J4B 7K8
Submission Control No: 204109
_ _
_Sandoz Fenofibrate E Page 2 of 43_
TABLE OF CONTENTS
PART 1: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................9
DRUG INTERACTIONS
..................................................................................................13
DOSAGE AND ADMINISTRATION
..............................................................................17
OVERDOSAGE
................................................................................................................18
ACTION AND CLINICAL PHARMACOLOGY
............................................................18
STORAGE AND STABILITY
..........................................................................................20
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................20
PART II: SCIENTIFIC INFORMATION
................................................................................22
PHARMACEUTICAL INFORMATION
..........................................................................22
CLINICAL TRIALS
..........................................................................................................23
DETAILED PHARMACOLOGY
............
Lees het volledige document
